EHA® 2023 Insights: "Preliminary Results From the Ph1/2 RUBY Trial of EDIT-301 in Patients With Severe Sickle Cell Disease Using Highly Specific and Efficient ASCAS12A Enzyme"

0 views
June 23, 2023
Comments 0
Login to view comments. Click here to Login